AU3457199A - Methods and compounds for modulating nuclear receptor activity - Google Patents

Methods and compounds for modulating nuclear receptor activity Download PDF

Info

Publication number
AU3457199A
AU3457199A AU34571/99A AU3457199A AU3457199A AU 3457199 A AU3457199 A AU 3457199A AU 34571/99 A AU34571/99 A AU 34571/99A AU 3457199 A AU3457199 A AU 3457199A AU 3457199 A AU3457199 A AU 3457199A
Authority
AU
Australia
Prior art keywords
atom
leu
receptors
receptor
nuclear receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34571/99A
Other languages
English (en)
Inventor
David A Agard
Geoffrey L. Greene
Peter J. Kushner
Andrew Shiau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Arch Development Corp
Original Assignee
University of California
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Arch Development Corp filed Critical University of California
Publication of AU3457199A publication Critical patent/AU3457199A/en
Priority to AU2003262215A priority Critical patent/AU2003262215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU34571/99A 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity Abandoned AU3457199A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003262215A AU2003262215A1 (en) 1998-03-30 2003-11-13 Methods and compounds for modulating nuclear receptor activity

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7995698P 1998-03-30 1998-03-30
US60079956 1998-03-30
US11314698P 1998-12-16 1998-12-16
US11301498P 1998-12-16 1998-12-16
US60113146 1998-12-16
US60113014 1998-12-16
PCT/US1999/006937 WO1999050658A2 (fr) 1998-03-30 1999-03-30 Methodes et composes de modulation d'activite de recepteurs nucleaires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003262215A Division AU2003262215A1 (en) 1998-03-30 2003-11-13 Methods and compounds for modulating nuclear receptor activity

Publications (1)

Publication Number Publication Date
AU3457199A true AU3457199A (en) 1999-10-18

Family

ID=27373576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34571/99A Abandoned AU3457199A (en) 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity

Country Status (6)

Country Link
EP (1) EP1144997A3 (fr)
JP (1) JP2002516983A (fr)
KR (1) KR20010042373A (fr)
AU (1) AU3457199A (fr)
CA (1) CA2324060A1 (fr)
WO (1) WO1999050658A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323575A1 (fr) * 1998-03-30 1999-11-25 Regents Of The University Of California Methodes et composes de modulation de la liaison d'un coactivateur a des recepteurs nucleaires
AU2818200A (en) * 1999-03-01 2000-09-21 Karo Bio Ab Homology models of the glucocorticoid receptor
CA2388253A1 (fr) * 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Structure cristallographique du domaine de liaison du ligand du recepteur androgene
FR2801311B1 (fr) * 1999-11-22 2005-08-26 Centre Nat Rech Scient Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d
CA2415103A1 (fr) * 2000-06-30 2002-01-10 The Regents Of The University Of California Procedes et composes pour moduler la fixation de coactivateurs a des recepteurs nucleaires
DE10036461A1 (de) * 2000-07-25 2002-02-07 Bayer Ag Ligandenbindedomäne des Ultraspiracle (USP)-Proteins
JP4593754B2 (ja) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 化学物質の５０％阻害濃度決定方法
JP2002296282A (ja) * 2001-04-02 2002-10-09 Enbiotec Laboratories:Kk 外因性内分泌攪乱物質の検出方法
WO2003004458A1 (fr) * 2001-07-03 2003-01-16 Biovitrum Ab Composes nouveaux
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
WO2005022436A1 (fr) * 2003-08-29 2005-03-10 National Institute Of Advanced Industrial Science And Technology Systeme d'affichage tridimensionnel d'une structure proteique pour l'indication du mecanisme de manifestation de la fonction proteique
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
WO2005040212A2 (fr) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Commutateurs geniques orthogonaux
KR20110110052A (ko) * 2010-03-31 2011-10-06 (주)아모레퍼시픽 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물
CA2800673A1 (fr) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Modulateur du recepteur oestrogenique et utilisation de ces derniers
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP0773227A1 (fr) * 1991-09-18 1997-05-14 Affymax Technologies N.V. Collections d'oligomères diverses, utiles pour préparer des médicaments, réactifs diagnostiques pesticides et herbicides
JP3394777B2 (ja) * 1993-05-27 2003-04-07 セレクタイド コーポレーション 位相学的に分離された、コードされた固相ライブラリー
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
AU717743B2 (en) * 1995-12-13 2000-03-30 Regents Of The University Of California, The Nuclear receptor ligands and ligand binding domains

Also Published As

Publication number Publication date
KR20010042373A (ko) 2001-05-25
WO1999050658A3 (fr) 2001-08-16
WO1999050658A2 (fr) 1999-10-07
EP1144997A3 (fr) 2002-08-28
EP1144997A2 (fr) 2001-10-17
JP2002516983A (ja) 2002-06-11
CA2324060A1 (fr) 1999-10-07

Similar Documents

Publication Publication Date Title
AU3457199A (en) Methods and compounds for modulating nuclear receptor activity
AU5769099A (en) Methods and compounds for modulating nuclear receptor coactivator binding
Pereira de Jésus‐Tran et al. Comparison of crystal structures of human androgen receptor ligand‐binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity
AU775928B2 (en) Crystallographic structure of the androgen receptor ligand binding domain
Dauter et al. Practical experience with the use of halides for phasing macromolecular structures: a powerful tool for structural genomics
Kosteria et al. The use of proteomics in assisted reproduction
EP1034184A2 (fr) Ligands de recepteurs nucleaires et domaines de liaison aux ligands
WO2016201257A2 (fr) Compositions et procédés d'identification de sites de ribosylation de l'adp par spectrométrie de masse
Sakhi et al. MAN1B1-CDG: Three new individuals and associated biochemical profiles
WO2002002488A9 (fr) Procedes et composes pour moduler la fixation de coactivateurs a des recepteurs nucleaires
Zhang et al. Proteomic signatures of infiltrative gastric cancer by proteomic and bioinformatic analysis
Esteves et al. Clinical Factors Impacting Microdissection Testicular Sperm Extraction Success in Hypogonadal Men with Nonobstructive Azoospermia
Trauger et al. Investigating viral proteins and intact viruses with mass spectrometry
Wu et al. Two-dimensional identification and localization of isomers in crystallin peptides using TWIM-MS
AU2003262215A1 (en) Methods and compounds for modulating nuclear receptor activity
Sriswasdi In-depth analysis of zero-length crosslinking for structural mass spectrometry
WO2004094591A2 (fr) Structures tridimensionnelles de hdac9 et cabin1 et structures de composes et procedes connexes
An et al. N-glycoproteomic Profiling Revealing New Coronavirus Therapeutic Targets That Maybe Involved in Cepharanthine’s Intervention
Shi et al. Mouse stromal cells confound proteomic characterization and quantification of xenograft models
Mojumdar et al. Advances in mass spectrometry-based approaches for characterizing monoclonal antibodies: resolving structural complexity and analytical challenges
Lee et al. Mass Spectrometry-based Comparative Analysis of Membrane Protein: High-speed Centrifuge Method Versus Reagent-based Method
Hancock et al. Glycoprotein (Glycan) Markers for the Early Detection of Breast Cancer
Muller et al. Signal Traitment and Virtual Images Production (2/2) Visualization and Analysis of Molecular Scanner Peptide Mass Spectra.(Muller et al., 2002)
Leung Integrating High-Throughput Technologies for the Identification and Validation of Novel Ovarian Cancer Biomarkers
WO2003095487A2 (fr) Complexes immunogenes

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted